scholarly journals Non-invasive monitoring of low molecular weight biomarkers relevant to skin inflammation and cancer

Author(s):  
◽  
Skaidre Jankovskaja

Development of skin inflammation and cancer in viable epidermis and dermis involve slow molecular weight (LMW) metabolites. We hypothesize that these LMW compounds can be collected on the surface of the skin and used for non-invasive diagnostics of skin disorders. Keeping in mind that substantial transdermal penetrationis achieved only for molecules of < 500 Da, we focused on topical monitoring of LMW biomarkers. In this thesis we investigated non-invasive, topical methods for monitoring LMW biomarkers by relevant in vitro and in vivo experiments. The LMW biomarkers were: - reactive oxygen species (ROS), specifically, hydrogen peroxide, H2O2 - amino acids and their derivatives, i.e., tryptophan (Trp), kynurenine (Kyn; a Trpderivative), phenylalanine (Phe), and tyrosine (Tyr; a Phe derivative). Initially, we have carried out in vitro experiments using dermatomed porcine skin and cell cultures. We characterized permeability of the biomarkers through skin and assessed methods of their monitoring. By using Prussian white particles, deposited on porcine skin, we demonstrated that hydrophilic biomarkers, such as H2O2, permeate the skin mainly through hair follicle pathways (Paper I). In paper II, we have showed that the enzymes transforming Trp to the inflammation and cancer biomarker Kyn, are expressed in the basal layer of epidermis. The magnitude of changes of the Trp/Kyn ratio in the cell culture model was assessed. In paper III, we have characterized Trp and Kyn permeability through skin in vitro, concluding that their permeabilities through stratum corneum are comparable. By in vivo experiments outlined in Paper IV, we have demonstrated the feasibility of topical, non-invasive sampling of Trp and Kyn, in relation to other amino acids. Kyn detection was compromised by its low abundance on the skin. In paper V, we performed a proof-of-concept study in vivo and confirmed that non-invasive sampling of Trp and amino acids of similar abundance, such as Phe and Tyr, is more robust. We concluded that Phe/Trp ratio might be equally good biomarker of skin disorders as a predicted Trp/Kyn ratio. Summarizing, the results of this thesis provide basic knowledge for deeper clinical studies of non-invasive, topical sampling of hydrophilic LMW biomarkers of skin inflammation and cancer.

Author(s):  
Jayadeep R. Yadav ◽  
Swati C. Jagdale ◽  
Anuruddha R. Chabukswar

Background and Objective: Fluconazole (FLZ) is a novel triazole antifungistatic drug; topical administration of FLZ resulted in systemic absorption and skin inflammation, and thereby failed to achieve mycological eradication, resulting in low patient compliance and undermining therapy effectiveness. The aim of this study was to use the emulsion solvent evaporation technique to create FLZ-loaded nanosponges (NSs) using ethylcellulose (EC) and polyvinyl alcohol (PVA) as a stabiliser. Materials and Method: By varying the drug concentration (FLZ), EC, and PVA, four formulations were developed, each of which was then optimized through particle characterization (polydispersity index (PDI), scanning electron microscopy (SEM), zeta potential (ZP), drug entrapment, and loading efficiency). Results: SEM (Scanning Electron Microscope) analysis showed that the particle sizes of FLZ inclusion complexes ranged from 150 2 to 250 5 nm. The ZP was strong enough to produce stable formulations. FLZ was released from the nano sponges in a regulated manner for 24 hours in both in vitro and in vivo experiments. FTIR and DSC were used to validate the association of the FLZ with the nanosponges. The crystalline nature of FLZ was modified to an amorphous state due to the complexation with the nanosponges, according to an XRPD analysis. The FLZ nanosponges were found to be stable in a stability analysis. Conclusion: Therefore, ethyl cellulose-based nanosponges provide a novel method for controlling the release of FLZ for antifungal effects.


Author(s):  
Bahman Rahimi Esboei ◽  
Masoud Keighobadi ◽  
Hajar Ziaei Hezarjaribi ◽  
Mahdi Fakhar ◽  
Ahmad Daryani ◽  
...  

Background: Toxoplasmosis is a disease that results from infection with an obligate intracellular T. gondii parasite, one of the world's most common parasites. Considering the complications of chemical drugs and the need for an appropriate drug combination for treatment of toxoplasmosis and also considering the antimicrobial potential of chitosan, as a natural source, this study was aimed to evaluate in vitro activity of commercial chitosan (CC) on T. gondii. Methods: In this experimental study, the tachyzoites of T. gondii was collected from the peritoneal exudates from infected Balb/c mice. The tachyzoites were diluted in phosphate buffer saline (PBS). Chitosan with low molecular weight was commercially purchased. Then, at concentrations of 10, 50, 100 and 200 µg/mL and after 30, 60, 120 and 180 minutes the viability of tachyzoites were determined by using trypan blue 0.1%. Anti-T.gondii activity of CC in all concentration was significantly higher than pyrimethamine as control group (P=0.05). Results: The concentration of 200 µg/mL of CC had the highest effects and killed 30.5, 52, 59 and 81.5% of tachyzoites after 30, 60, 120 and 180 minutes. Moreover, IC50 values of CC were 515, 171, 12.5 and <10 μg/mL in comparison with pyrimethamine as 58.82 μg/mL for 30, 60, 120, and 180 min of exposure time. Conclusion: Our results indicate chitosan in low molecular weight had potent activity against T. gondii tachyzoites and could be an appropriate candidate for treatment of at least acute toxoplasmosis, certainly, after complementary in vivo experiments.


2019 ◽  
Vol 1 (1) ◽  
pp. 22-28
Author(s):  
D. S. Vorobyev ◽  
I. B. Semenova ◽  
Yu. V. Volokh ◽  
E. E. Romanenko ◽  
A. P. Baturo ◽  
...  

Aim. The study of immunochemical and immunobiological properties of native protein-containing antigens of pneumococcus. Materials and methods. The study was carried out on the strains of the Collective Usage Center «Collection of Mechnikov Res. Inst. for Vaccine and Sera». In the work studied the chemical composition, the molecular weight of the obtained antigens in SDS-electrophoresis and antibody titers in ELISA. Protective activity of protein-containing antigens of pneumococcus was determined in experiments of active protection of mice. Results. Protein-containing antigens of pneumococcus were isolated from S. pneumoniae serotypes 3, 6B, 10A, 14, 19F, 23F and 36. The chemical composition of the preparations contained from 16 to 35% protein. In SDS-electrophoresis in polyacrylamide gel it was established that the molecular weight of protein-containing antigens of pneumococcus ranged from 14 to 116 kDa. Using ELISA shows the cross-activity of native antigens. Virtually all drugs reacted with antimicrobial rabbit serum obtained to serotype 19F (p≤0.05). Serotype serum 14 was less active and only protein-containing pneumococcal antigens obtained from 14 and 19F serotypes (p≤0.05) interacted with it. In the precipitation test according to Ouchterlony it was confirmed that preparations of serotypes 3, 6B, 14, 19F and 36 reacted with rabbit immune serum obtained for S. pneumoniae 19F serotype. In immunoblotting it was found that protein-containing antigens of pneumococcus isolated from serotypes 3, 6B, 10A, 14, 19F and 36 were associated with monoclonal antibodies to pneumococcal protein — pneumolysin. In vivo experiments it was shown that protein-containing antigens of pneumococcus protected animals from intraperitoneal infection of S. pneumoniae in homologous and heterologous systems (p≤0.05). Conclusion. The revealed immunochemical and cross-protective activity of protein-containing antigens of pneumococcus in vitro and in vivo experiments allows to select drugs derived from serotypes 6B, 10A, 19F and 36, as the most promising for further study of the intraspecific protective activity of individual native proteins of pneumococcus. 


2021 ◽  
Author(s):  
zhu yu ◽  
Wenlong Cao ◽  
Chuangye Han ◽  
Zhen Wang ◽  
Yue Qiu ◽  
...  

Abstract In recent years, sonodynamic therapy (SDT) has been widely developed for cancer research as a promising non-invasive therapeutic strategy. Here, we synthesized Zeolitic imidazole frameworks-8 (ZIF-8) and utilized its properties to encapsulate hydrophobic Chlorin e6 (Ce6) and hydrophilic tirapazamine (TPZ) for a synergistic sonodynamic-chemotherapy, which was also accompanied by the modification of cytomembrane of gastric cancer (GC) cells. Thus, we enabled the biomimetic property to achieve targeted delivery. Ce6-mediated SDT, in combination with ultrasound irradiation, could target the release of reactive oxygen species (ROS) to aggravate further hypoxia, which activated TPZ. Combining these effects could induce the pyroptosis of GC cells. Both in vitro and in vivo experiments showed that the nanoparticle had good biocompatibility and anti-cancer function, which could provide a potential therapeutic method for cancer therapy.


1988 ◽  
Vol 53 (11) ◽  
pp. 2944-2951 ◽  
Author(s):  
Günter Losse ◽  
Wolfgang Naumann ◽  
Heike Raddatz ◽  
Joachim Koszowicz

Polyglycine, polyalanine, polyleucine, poly-α-glutamic acid, poly-γ-glutamic acid and poly-α-lysine were complexed with insulin under non-denaturating conditions. The liberation behaviour of the hormone was investigated in vivo and in vitro in dependence on the insulin content, molecular weight, ionic interactions and hydrophobicity of the polyamino acid. The in vitro results were confirmed by the in vivo experiments with animals. They clearly pointed out the influence of physicochemical parameters on the bioavailability of insulin. Complexes of poly-α-lysine and polyglycine were shown to be the most suitable retard forms, producing significant blood glucose lowering effects over 12 hours.


2018 ◽  
Vol 9 (3) ◽  
pp. 435-439
Author(s):  
О. О. Boyko ◽  
O. G. Gavrilina ◽  
P. N. Gavrilin ◽  
Y. A. Gugosyan ◽  
V. V. Brygadyrenko

Formic acid (methanoic acid, HCOOH) is an organic compound which belongs to saturated monobasic acids. In natural conditions, it is secreted from the glands of ants, and also extracted from the leaves of stinging nettles. It is soluble in water in any proportions, which makes it practical to use for making aquatic solutions. It is broadly used as a preservative in the food industry – Е236 food additive (Codex Alimentarius), as a bactericide in medicine and veterinary medicine, and is also used against agricultural pest species of insects and mites. The in vitro and in vivo experiments revealed the anthelmintic properties of the acid against Strongyloides papillosus nematodes, parasites of the gastrointestinal tract of Ruminantia and rabbits. In the conditions of in vitro, 100% of (L1, L2, L3) nematode larvae died from a 1% solution of formic acid (10 g/l) after 24 hours exposure. When exposed to less strong concentrations of the acid (1, 0.1, 0.01, 0.001 g/l), vital forms of L3 S. papillosus were found. Non-invasive stages (L1, L2) are less resistant to the impact of the acid – death of 100% of the larvae was observed under the impact of 0.1% solution and up to 60% of larvae died at 0.01% solution of formic acid in the same conditions. LD50 for L3 invasive larvae of S. papillosus equaled 0.47%, and 0.0076% for L1, L2 non-invasive larvae of S. papillosus. In the conditions of in vivo experiment (with guinea pigs), the effective dose of formic acid was 0.4% ml/kg of the animal`s body weight. The results of the coproscopy after the treatment demonstrated absence of the helminth larvae in the feces of the laboratory animals during 10 days and their occurrence only on days 15–20 with a low intensity (90 larvae/g of feces on average). During an external examination of the corpses of the animals of the experimental group, no pathological changes were found. The intestine, the heart, the lungs and the liver of the animals from this group had no macroscopic changes – they were of natural colour and size. The hepatocytes looked normal and the structure of the liver lobes was maintained. In the tissues of the liver of the animals from the experimental and control groups, we found processes of passive congestion, and an insignificant degree of signs of hepatic steatosis.


1994 ◽  
Vol 72 (06) ◽  
pp. 942-946 ◽  
Author(s):  
Raffaele Landolfi ◽  
Erica De Candia ◽  
Bianca Rocca ◽  
Giovanni Ciabattoni ◽  
Armando Antinori ◽  
...  

SummarySeveral “in vitro” and “in vivo” studies indicate that heparin administration may affect platelet function. In this study we investigated the effects of prophylactic heparin on thromboxane (Tx)A2 biosynthesis “in vivo”, as assessed by the urinary excretion of major enzymatic metabolites 11-dehydro-TxB2 and 2,3-dinor-TxB2. Twenty-four patients who were candidates for cholecystectomy because of uncomplicated lithiasis were randomly assigned to receive placebo, unfractionated heparin, low molecular weight heparin or unfractionaed heparin plus 100 mg aspirin. Measurements of daily excretion of Tx metabolites were performed before and during the treatment. In the groups assigned to placebo and to low molecular weight heparin there was no statistically significant modification of Tx metabolite excretion while patients receiving unfractionated heparin had a significant increase of both metabolites (11-dehydro-TxB2: 3844 ± 1388 vs 2092 ±777, p <0.05; 2,3-dinor-TxB2: 2737 ± 808 vs 1535 ± 771 pg/mg creatinine, p <0.05). In patients randomized to receive low-dose aspirin plus unfractionated heparin the excretion of the two metabolites was largely suppressed thus suggesting that platelets are the primary source of enhanced thromboxane biosynthesis associated with heparin administration. These data indicate that unfractionated heparin causes platelet activation “in vivo” and suggest that the use of low molecular weight heparin may avoid this complication.


1964 ◽  
Vol 12 (01) ◽  
pp. 232-261 ◽  
Author(s):  
S Sasaki ◽  
T Takemoto ◽  
S Oka

SummaryTo demonstrate whether the intravascular precipitation of fibrinogen is responsible for the toxicity of heparinoid, the relation between the toxicity of heparinoid in vivo and the precipitation of fibrinogen in vitro was investigated, using dextran sulfate of various molecular weights and various heparinoids.1. There are close relationships between the molecular weight of dextran sulfate, its toxicity, and the quantity of fibrinogen precipitated.2. The close relationship between the toxicity and the precipitation of fibrinogen found for dextran sulfate holds good for other heparinoids regardless of their molecular structures.3. Histological findings suggest strongly that the pathological changes produced with dextran sulfate are caused primarily by the intravascular precipitates with occlusion of the capillaries.From these facts, it is concluded that the precipitates of fibrinogen with heparinoid may be the cause or at least the major cause of the toxicity of heparinoid.4. The most suitable molecular weight of dextran sulfate for clinical use was found to be 5,300 ~ 6,700, from the maximum value of the product (LD50 · Anticoagulant activity). This product (LD50 · Anticoagulant activity) can be employed generally to assess the comparative merits of various heparinoids.5. Clinical use of the dextran sulfate prepared on this basis gave satisfactory results. No severe reaction was observed. However, two delayed reactions, alopecia and thrombocytopenia, were observed. These two reactions seem to come from the cause other than intravascular precipitation.


1986 ◽  
Vol 56 (03) ◽  
pp. 318-322 ◽  
Author(s):  
V Diness ◽  
P B Østergaard

SummaryThe neutralization of a low molecular weight heparin (LHN-1) and conventional heparin (CH) by protamine sulfate has been studied in vitro and in vivo. In vitro, the APTT activity of CH was completely neutralized in parallel with the anti-Xa activity. The APTT activity of LHN-1 was almost completely neutralized in a way similar to the APTT activity of CH, whereas the anti-Xa activity of LHN-1 was only partially neutralized.In vivo, CH 3 mg/kg and LHN-1 7.2 mg/kg was given intravenously in rats. The APTT and anti-Xa activities, after neutralization by protamine sulfate in vivo, were similar to the results in vitro. In CH treated rats no haemorrhagic effect in the rat tail bleeding test and no antithrombotic effect in the rat stasis model was found at a protamine sulfate to heparin ratio of about 1, which neutralized APTT and anti-Xa activities. In LHN-1 treated rats the haemorrhagic effect was neutralized when APTT was close to normal whereas higher doses of protamine sulfate were required for neutralization of the antithrombotic effect. This probably reflects the fact that in most experimental models higher doses of heparin are needed to induce bleeding than to prevent thrombus formation. Our results demonstrate that even if complete neutralization of APTT and anti-Xa activities were not seen in LHN-1 treated rats, the in vivo effects of LHN-1 could be neutralized as efficiently as those of conventional heparin. The large fall in blood pressure caused by high doses of protamine sulfate alone was prevented by the prior injection of LHN-1.


1979 ◽  
Vol 42 (03) ◽  
pp. 885-894 ◽  
Author(s):  
Tatsuo Ueno ◽  
Norio Kobayashi ◽  
Tadashi Maekawa

SummaryPharmacokinetics of intravenously injected 125I-labeled urokinase (125I-UK) of a molecular weight of 33,000 daltons in normal rabbits and patients with various diseases were investigated. The plasma clearance of 125I-UK in rabbits was described by a biexponential curve within six hours with a half-life of 8 minutes, 2.3 hours, respectively. The radioactivity in the liver and kidneys 15 minutes after iv injection with 125I-UK was 9.6% and 14.0% of the radioactivity injected, respectively. Approximately 80% of the total radioactive material injected was excreted in the urine in 18 hours. No increase in activator activity in the urine was observed after a large amount of UK injection. Activity uptake of 125I-UK by experimentally induced arterial thrombus was little. Lysis of the stasis thrombus was produced by injecting 7.5 × 104 IU of UK in only one out of 8 rabbits. In vitro contact experiment revealed that transfer of 125I-UK to plasma clot is slow (24 hours for 10% of 125I-UK by plasma clot). In 4 patients plasma clearance of 125I-UK was essentially similar to that in rabbits. From the results obtained optimal dosage regimen of UK administration for complete thrombolysis in vivo was discussed.


Sign in / Sign up

Export Citation Format

Share Document